This is not surprising, since divergent semaphorin functions in neurons and in cancer cells are commonly seen (e.g. for Sema3A, Sema3E, Sema4D, etc.), likely reflecting the involvement of different receptor complexes and signaling pathways [1, 42, 43]. This evidence concerns the gene SEMA3A and cancer.